Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1GATA2 Deficiency 1Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 6atezolizumab 5Cisplatin 5Ipilimumab 4Carboplatin 4Etoposide 3pembrolizumab 2gallium Ga 68 dotatate 2dostarlimab 2Temozolomide 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Magnetic Resonance Imaging 2Irinotecan 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Disulfides 2zimberelimab 1tivozanib 1repotrectinib 1niraparib 1lutetium Lu 177 dotatate 1lenvatinib 1iadademstat 1durvalumab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × iadademstat × 1 year × Clear all
NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡